课程介绍
大家好，我是 Lian van der Gang。我是一名医学博士，来自荷兰乌得勒支。很高兴能和我的同事们一起参加 2025 年的 EADV 会议，并展示一些 BioDay 登记研究数据。 我们在荷兰建立 BioDay 登记系统已超过 7 年。我们自豪于整个团队一起收集的患者信息。因此，今年我们能够展示第一项比较数据。这是非常激动人心的时刻。随着我们对治疗特应性皮炎的生物制剂和 JAK 抑制剂了解越来越多，我们现在能够做第一项与生物制剂和 JAK 抑制剂有关的真实世界比较研究。
去年，我们在接受生物制剂和 JAK 抑制剂治疗的患者中进行了与感染相关的研究。今年，我们做了一项真实世界比较研究，在度普利尤单抗和曲罗芦单抗之间做比较。我们同时研究了有效性——真实世界中的有效性，以及安全性。 在周三上午的欧洲特应性皮炎工作组（ETFAD）会议上，我展示了相关数据：与曲罗芦单抗相比，度普利尤单抗的有效性略高一些，但差异非常小。我认为和临床医生讨论是很有趣的。
此外，我们今年也有一张壁报研究，关于不同生物制剂和 JAK 抑制剂的药物留存率：度普利尤单抗、曲罗芦单抗、乌帕替尼、阿布昔替尼和巴瑞替尼都有涉及到。结果表明度普利尤单抗的药物留存率高于其他疗法。我们还特别观察了生物制剂和 JAK 抑制剂初治的患者群体，因为这些患者更容易产生更好的应答，他们在既往的治疗中没有失败过。这里我们看到了相同的模式：度普利尤单抗在上述患者中的药物留存率也最高。然而，与整个人群相比，其他治疗方法之间药物留存率的差异较小。最后，我们分享了关于结节性痒疹的最新数据：患者接受度普利尤单抗治疗 52 周后的真实疗效和安全性。这同样令人兴奋。希望能早日公布研究结果。
Hello everyone. My name is Lian van der Gang. I’m a medical doctor, PhD student from Utrecht in the Netherlands. I’m very happy to be here at the EADV conference of 2025 together with my colleagues, and be able to present some of our BioDay Registry data. We had the BioDay Registry in the Netherlands for over seven years. We’re very proud of the data we have collected together with our whole team and all of our patients. So this year we are able to present some of our first comparative data. I think these are very exciting times. As we gain more and more knowledge on the biologics and the JAK inhibitors for the treatment of atopic dermatitis, we are now actually able to do the first real-world comparative studies between these biologics and JAK inhibitors.
Last year, we were able to present our research on infections in both patients treated by biologics and JAK inhibitors. This year we did a real-world comparison study of dupilumab versus tralokinumab. We looked at both efficacy—effectiveness actually in real world—and also safety. At the ETFAD Meeting on Wednesday morning, I presented our data, and we see that dupilumab is slightly more effective than tralokinumab. However, the difference is quite small. So I think it’s really interesting to debate with fellow clinicians.
Furthermore, we have also had a poster this year on drug survival of the different biologics and JAK inhibitors: dupilumab, tralokinumab, upadacitinib, abrocitinib, baricitinib—actually all the ones we have available. We saw that dupilumab drug survival was superior to the other treatments. We specifically also looked at the biological- and JAK-inhibitor-naïve patients, because these patients are more likely to respond better; they have not failed on previous treatments. There we actually saw the same pattern: dupilumab was also the treatment with the longest drug survival. However, the drug survival between the other treatments was less different than with the whole population. Finally, we also are able to share our new data on prurigo nodula
